ATACC-RA
Cardio-Rheumatology Registry & Risk Observatory
Therapeutic Surveillance Matrix · ORAL Surveillance & Registry Data

DMARD, Biologic & JAK Inhibitor Cardiovascular Safety

Controlling rheumatoid synovitis lowers vascular events with methotrexate and TNF inhibitors, whereas chronic glucocorticoids and high-risk JAK inhibitor profiles carry distinct MACE and VTE signals.

Pre-Prescribing JAKi & Steroid Safety Gate

Toggle patient flags prior to initiating a JAK inhibitor or continuing oral prednisone.

HIGH HAZARD GATE: AVOID JAKi & TAPER STEROID

Rheumatologist performing joint evaluation with an automated blood pressure monitor nearby in outpatient clinic
Plate 03: Joint-count surveillance paired with routine blood pressure checks identifies glucocorticoid hypertension early. Rheumatology Clinic

Cardiovascular Signal Comparison by Drug Class

Evidence Synthesis

Observational registries and randomized head-to-head trials demonstrate an approximate 21% to 30% lower MACE incidence in methotrexate and TNF-inhibitor responders, neutral MACE parity for tocilizumab versus etanercept in ENTRACTE (HR 1.05), and a non-inferiority miss for tofacitinib versus TNF inhibitors in high-risk ORAL Surveillance cohorts (HR 1.33, 95% CI 0.91-1.94).

Sources: Ytterberg et al., NEJM 2022 (ORAL Surveillance) and ENTRACTE Trial.

Table 1: Cardiovascular Event Signals & Monitoring Mandates Across RA Therapies
Agent / Class MACE Signal (HR / Effect) VTE / Blood Pressure Note Baseline & Follow-Up Action
Methotrexate (MTX) ~21% MACE reduction in RA cohorts Neutral VTE; lowers inflammatory endothelial stress Anchor csDMARD; avoid NSAID overuse for pain flares
Hydroxychloroquine (HCQ) Favorable glycemic & lipid profile Rare QTc prolongation at high dose or renal impairment Screen ECG if combined with other QTc agents
TNF Inhibitors (Adalimumab / Etanercept) Reference protective bDMARD (~30% drop) Avoid in NYHA Class III-IV heart failure Re-check fasting lipids once DAS28 < 3.2
IL-6R Blockers (Tocilizumab / Sarilumab) HR 1.05 vs Etanercept (ENTRACTE) Raises LDL/HDL 15-25% via CRP normalization Check fasting lipids & ApoB at week 8-12; add statin if indicated
JAK Inhibitors (Tofacitinib / Baricitinib / Upadacitinib) HR 1.33 vs TNFi (ORAL Surveillance) Elevated DVT/PE VTE risk in age >= 65 or smokers Restrict in age >= 65, smokers, or ASCVD unless no alternative
Oral Prednisone (>= 7.5 mg/day) HR 1.48 dose-dependent MACE jump Worsens systolic BP, insulin resistance, and dyslipidemia Use short bridging only; taper below 5 mg/day aggressively

Comparative Hazard Ratio Forest Plot (Reference Benchmark = 1.0)

MACE Hazard Ratio Forest Plot Across RA Therapies HR 1.0 Methotrexate (Meta-analysis) HR 0.79 (0.68-0.91) Tocilizumab vs Etanercept (ENTRACTE) HR 1.05 (0.77-1.43) Tofacitinib vs TNFi (ORAL Surv.) HR 1.33 (0.91-1.94) Prednisone >= 7.5mg/d Chronic HR 1.48 (1.16-1.88)